Friday, November 20, 2026
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO NA Magazine > CEO Life > Health > New blood tests may revolutionize Alzheimer’s diagnosis

New blood tests may revolutionize Alzheimer’s diagnosis

in Health
New blood tests may revolutionize Alzheimer’s diagnosis
Share on LinkedinShare on WhatsApp

New blood tests could significantly improve the speed and accuracy of diagnosing Alzheimer’s disease, according to recent research presented at the Alzheimer’s Association International Conference. These tests aim to detect the presence of beta-amyloid, a protein that accumulates in the brain and is a hallmark of Alzheimer’s, potentially replacing the need for more invasive procedures like brain scans or spinal taps. Currently, diagnosis often relies on symptom assessment and cognitive exams, which can be imprecise.

A study involving about 1,200 patients in Sweden demonstrated the potential of these blood tests in routine clinical settings. Conducted by Lund University researchers, the study found that while traditional diagnostic methods had an accuracy rate of 61% for primary care doctors and 73% for specialists, the blood tests achieved a 91% accuracy rate. This finding suggests that blood tests could be a valuable tool in diagnosing Alzheimer’s, particularly in primary care settings where resources for specialized testing are limited.

Despite their promise, these blood tests are not yet widely used due to limited data on their reliability, lack of FDA approval, and minimal insurance coverage. Over 6 million Americans and millions more worldwide suffer from Alzheimer’s, which is characterized by amyloid plaques and abnormal tau protein in the brain. New drugs, such as Leqembi and Kisunla, offer some hope by slowing the disease’s progression, but are only effective in its early stages, highlighting the need for timely and accurate diagnosis.

Tags: Alzheimer's AssociationAlzheimer's DiseaseCEOLund University

Related Posts

U.S. Loses Measles-Free Status After 26 Years
Health

U.S. Loses Measles-Free Status After 26 Years

To be successful in 2025, a therapist says do these 5 things: It works ‘any time of year’
Health

Why switching off from work is so hard

How to Fall Asleep in 10, 60, or 120 Seconds
Health

How to Fall Asleep in 10, 60, or 120 Seconds

High Carb Foods That Are Incredibly Healthy
Health

High Carb Foods That Are Incredibly Healthy

Why ‘Binge-Watching’ That TV Show Now May Affect Your Brain Later
Health

Why ‘Binge-Watching’ That TV Show Now May Affect Your Brain Later

Get Your Vitamin P: Why Pleasure Matters When It Comes to What You Eat
Health

Get Your Vitamin P: Why Pleasure Matters When It Comes to What You Eat

Can Collagen Really Improve Your Skin Health? What the Research Says
Health

Can Collagen Really Improve Your Skin Health? What the Research Says

What Type of Procrastinator Are You?
Health

What Type of Procrastinator Are You?

Stretches to Do Before Bed
Health

Stretches to Do Before Bed

Consumers Plan to Let Restaurants Do the Cooking During the Holidays
Health

How Staying Social Can Help to Prevent Dementia

No Result
View All Result

Recent Posts

  • Why are we so obsessed with the ’90s?
  • U.S. Loses Measles-Free Status After 26 Years
  • Plane clapping – joyful or deeply cringe?
  • The 4 themes shaping new manufacturing
  • Anthropic’s total raised reaches $93.5 billion after underwriters’ greenshoe overallotment

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.